Update of endoscopy in liver disease

Citation for published version:

Digital Object Identifier (DOI):
10.3748/wjg.v18.i5.401

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
World journal of gastroenterology : WJG

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Update of endoscopy in liver disease: More than just treating varices

Christoforos Krystallis, Gail S Masterton, Peter C Hayes, John N Plevris

Abstract

The management of complications in liver disease is often complex and challenging. Endoscopy has undergone a period of rapid expansion with numerous novel and specialized endoscopic modalities that are of increasing value in the investigation and management of the patient with liver disease. In this review, relevant literature search and expert opinions have been used to provide a brief overview and update of the current endoscopic management of patients with liver disease and portal hypertension. The main areas covered are safety of endoscopy in patients with liver disease, the use of standard endoscopy for the treatment of varices and the role of new endoscopic modalities such as endoscopic ultrasound, esophageal capsule, argon plasma coagulation, Spyglass and endomicroscopy in the investigation and treatment of liver-related gastrointestinal and biliary pathology. It is clear that the role of the endoscopist in liver disease is well beyond that of just treating varices. As the technology in endoscopy expands, so does the role of the endoscopist in liver disease.

© 2012 Baishideng. All rights reserved.
Coagulopathy and thrombocytopenia are common in patients with chronic liver disease. The mechanisms behind coagulation abnormalities are often complex, and it is now thought that prolongation of prothrombin time may not directly relate to the risk of bleeding, and rather, it is the balance of pro- and antithrombotic factors that is important. In practical terms, there is currently no reliable way of quantifying this. Routine correction of coagulopathy at endoscopy is not recommended, although patients with chronic liver disease should receive vitamin K to correct any dietary deficiency that may result in coagulopathy.

It is recognized that diagnostic endoscopy is a low-risk procedure and safe in patients with altered coagulation. However, high-risk endoscopic therapeutic procedures have a significantly increased risk of hemorrhage and, as such, coagulopathy should be treated. It is therefore common practice in cirrhotic patients to correct significant thrombocytopenia (\(< 50 \times 10^3/\text{mL}\)) with platelet transfusions and to correct coagulopathy with fresh frozen plasma (FFP) if prothrombin time is > 20 s to an international normalized ratio < 1.5, before high-risk procedures. Platelet and FFP transfusions are particularly helpful during an acute bleeding episode if the prothrombin time is prolonged or platelets are low; similar to the previously mentioned values.

Novel treatments include recombinant factor VIIa. This has been used as a hemostatic agent in acute variceal bleeding, but failed to show efficacy in a randomized study. Another trial has demonstrated that addition of desmopressin does not improve and may worsen the efficacy of terlipressin in controlling acute variceal bleeding in cirrhotic patients.

Certain endoscopic investigations have been shown to be safe in coagulopathic patients with cirrhosis, despite being relatively invasive; EUS-fine needle aspiration of the liver has been shown to be a safe alternative to percutaneous liver biopsy, particularly in patients with advanced liver disease, coagulopathy and high risk of bleeding. At endoscopic retrograde cholangiopancreatography (ERCP), endoscopic papillary balloon dilation is safer than endoscopic biliary sphincterotomy for the treatment of choledocholithiasis in patients with advanced cirrhosis and coagulopathy, because it has a reduced risk of bleeding.

### COMMON ENDOSCOPIC DIAGNOSES AND MANAGEMENT IN PATIENTS WITH LIVER DISEASE

#### Peptic ulcer disease

The correlation between peptic ulcer disease and cirrhosis is well described. Both duodenal and gastric ulcers are more common in cirrhosis: the reported prevalence is 24.1%\(^1\). It is recognized that the prevalence of gastric ulceration increases with the severity of liver disease and is related to changes in the hepatic venous pressure gradient\(^2\).

A high prevalence of *Helicobacter pylori* (H. pylori), up
to 89%, in patients with cirrhosis has been reported\(^{18}\). 13C urea breath testing and gastric body histology remain highly accurate in detecting *H. pylori* in cirrhosis, whereas rapid urease tests and serology are less reliable than in non-cirrhotic patients\(^{19}\). A meta-analysis of seven studies with almost 1000 patients has strongly suggested that, as with non-cirrhotic patients, *H. pylori* infection increases the risk for peptic ulcer disease in cirrhosis\(^{20}\). *H. pylori* eradication therapy is effective in chronic liver disease\(^{21}\). However, two recent studies have suggested that *H. pylori* eradication in cirrhotic patients with duodenal ulcers is not as effective at reducing ulcer recurrence as it is in the general population. These patients require maintenance acid suppression therapy\(^{22,23}\).

### Portal hypertension

The development of portal hypertension and formation of portosystemic shunts is a major event in the natural history of liver disease. Measurement of the portal pressure gradient is invasive and not widely available for clinical use; instead the hepatic venous pressure gradient (HVPG) is commonly used in clinical practice and it is of prognostic value: HPVG ≥ 10 mm Hg strongly predicts the development of esophageal varices\(^{24}\). Similarly, the most significant risk factor associated with failure to control bleeding or early rebleeding of esophageal varices is HVPG > 20 mm Hg. This is also associated with increased mortality\(^{25}\).

Gastroesophageal varices are present in > 50% of patients with portal hypertension and are more likely as liver disease progresses\(^{26}\). Ectopic varices are located in sites other than the gastroesophageal region and are more common than previously thought: duodenal or colonic varices are seen at angiography or colonoscopy in up to 40% of patients with intrahepatic portal hypertension\(^{27}\).

### Esophageal varices

It is recommended that all patients undergo endoscopy to assess the presence and the size of varices at the time of the diagnosis of cirrhosis. Thereafter, guidelines for the interval of endoscopic screening vary. Currently, the American Association for the Study of the Liver (AASLD) recommends that, if no varices are present at index endoscopy, this should be repeated at 2-3 years in compensated cirrhosis and annually in decompensated cirrhosis\(^{28}\). The British Society of Gastroenterology recommends annual screening if grade 1 varices are present at initial screening (Table 1, grading and treatment of esophageal varices), and an interval of 3 years if there is no evidence of varices at index endoscopy\(^{29}\).

Esophageal variceal bleeding occurs at a rate of 5%-15% per year in untreated patients. The main risk factors for bleeding are variceal size (grade 2 or 3), decompensated cirrhosis, and the presence of high-risk stigmata at endoscopy\(^{30}\). Variceal bleeding is a significant clinical event with a mortality rate of approximately 20% at 6 wk, and a recurrence rate of up to 60% at 2 years if secondary prophylaxis is not commenced\(^{31}\).

The management of esophageal varices may be divided into pre-primary, primary and secondary prophylaxis and control of active bleeding. At present, there is no evidence to support treatment to prevent the development of varices in patients with liver disease (pre-primary prophylaxis)\(^{11,28}\).

For primary prophylaxis of esophageal varices, there is no evidence that variceal band ligation (VBL) is superior to \(\beta\)-blockade. Due to issues with access to endoscopy and patient preference, non-selective \(\beta\)-blockade, typically with propranolol, is often first line when treatment is indicated\(^{32}\). Carvedilol is a potent non-selective \(\beta\)-blocker, with weak vasodilating properties. A reduction in the HVPG in the range of 10%-43% has been reported with a 12.5 mg/d dose. Carvedilol has therefore been adopted as the \(\beta\)-blocker of choice for primary prophylaxis of variceal bleeding in some centers\(^{33-35}\). Primary prophylaxis with VBL is recommended if there are contraindications to \(\beta\)-blockers, or concerns about patient compliance\(^{11}\).

Secondary prophylaxis is indicated for patients who have had an episode of variceal hemorrhage. \(\beta\)-blocker monotherapy is not used as secondary prophylaxis, and patients should either be entered into a variceal banding program or receive a combination of a \(\beta\)-blocker and nitrates\(^{36}\). AASLD recommends a combination of \(\beta\) blockade and VBL\(^{11}\). However, there is no strong evidence to suggest that this strategy is associated with improved mortality\(^{37}\) and our local practice is to use VBL alone. VBL should be repeated every 2 wk until obliteration of varices is achieved. Following this, a surveillance endoscopy at 1-3 mo to confirm eradication is required, and this should be repeated every 6-12 mo\(^{11}\). VBL is a safe technique: although asymptomatic banding ulcers are common after VBL, the rate of bleeding from these and requiring hospitalization does not exceed 5%\(^{38}\).

The combination of terlipressin and VBL is the preferred treatment for acute variceal bleeding in many centers, and using terlipressin before endoscopy is not unreasonable if there is a delay to the endoscopy.
scopic hemostasis is usually achieved in the majority of cases. Transjugular intraportal systemic shunt (TIPSS) may be considered if VBL has been unsuccessful or there is an early re-bleed (defined at Baveno V as a repeat bleed within 5 d of the index bleed). A reduction in HVPG below 12 mmHg or a 20% reduction from the baseline value, even without reaching < 12 mmHg, protects against rebleeding.

The use of sclerosing agents (variceal sclerotherapy) is no longer recommended as first-line treatment, because of increased mortality rates, nor for secondary prophylaxis because VBL treatment has been shown to be safer and more effective.

Recently, endoscopic placement of a specifically designed self-expanding covered metal stent has proved effective in the treatment of esophageal varices in patients in whom initial endoscopic methods have failed to achieve hemostasis. This method appears to be a safe and effective means of controlling ongoing bleeding. The stent is usually removed 1 wk after the acute bleed. Currently, this technique is limited by its relative complexity.

Gastric antral vascular ectasia (GAVE) when reporting the outcomes although the authors did not distinguish the etiology of GAVE-related bleeding, and it is extensively used in the treatment of GAVE and is the most commonly reported treatment of GAVE-related bleeding, and it is more common in patients with severe PHG.

Nonvariceal manifestations of portal hypertension
Portal hypertensive gastropathy (PHG), with its typical “snake skin” appearance, is present in approximately 80% of patients with cirrhosis. PHG accounts for 8% of nonvariceal bleeds in patients with liver disease, although this condition more commonly presents with anemia.

Patients with cirrhosis and severe PHG-related bleeding may respond to β-blockade. Endoscopic measures such as argon plasma coagulation (APC) therapy can reduce bleeding, thus controlling anemia. TIPSS should be reserved for those patients with pharmacological treatment failure.

The prevalence of portal hypertensive enteropathy (PHE), determined by capsule endoscopy, is as high as 63% in patients with end-stage liver disease who also have esophageal or gastric varices. Portal hypertensive duodenopathy is present in about half of patients with cirrhosis, and it is more common in patients with severe PHG.

Gastric antral vascular ectasia
Gastric antral vascular ectasia (GAVE) is related to portal hypertension in about 30% of patients, and accounts for 4% of nonvariceal upper GI bleeds. Unlike PHG, GAVE does not respond well to reduction in portal pressure. The Nd:YAG laser has been widely used in the treatment of GAVE and is the most commonly reported endoscopic modality in cirrhotic and non-cirrhotic patients, with a reported overall success rate of almost 90%, although the authors did not distinguish the etiology of GAVE when reporting the outcomes.

APC has also proved to be effective for the treatment of GAVE-related bleeding, and it is extensively used in our unit, with a success rate of > 85%; success is defined as control of bleeding, stabilization of hemoglobin at > 100 g/dL, or hemoglobin increase > 10% from pretreatment level, and reduction of transfusion requirements by > 50% in transfusion-dependent patients. An average of four sessions of APC is usually required.

In two published studies, with a total of 37 patients with cirrhosis, success rates in controlling bleeding were very high, and the reported rebleeding rates were between 12% and 20% after 2 years follow-up.

Although the success rates of the two aforementioned modalities are comparable, APC treatment is probably the therapy of choice due to the technical ease, safety and low cost. Other endoscopic techniques have been positively reported in small series, such as VBL.
endoscopic mucosal ablation and cryotherapy.

ADVANCED ENDOSCOPIC PROCEDURES AND THEIR VALUE IN LIVER DISEASE

EUS

Recently, EUS has been used to assist in the management of portal hypertension. Doppler EUS is of significant value in differentiating ectopic varices from other submucosal lesions (Figure 4), and several EUS-assisted techniques have been used to identify the precise site for the intravariceal injection of sclerosant agents. Linear color EUS-guided sclerotherapy has proved to be effective in the eradication of esophageal varices, in two small studies with recurrence reported at 0% and 8.3%, respectively.

Endoscopic mucosal ablation and cryotherapy.

Capsule endoscopy

Esophageal capsule endoscopy (OCE) is an alternative to conventional upper GI endoscopy for the diagnosis of varices in complex patients with portal hypertension. In a recent meta-analysis of seven studies involving 446 patients, OCE had a sensitivity of 85.8% and specificity 80.5% in detecting esophageal varices. However, a multicenter trial evaluating the efficacy of OCE in esophageal varices screening was less encouraging, because the standard of < 10% difference between capsule
and conventional endoscopy was not met\(^7\). This is not surprising, because the two techniques differ in that during conventional endoscopy, the esophagus is inevitably insufflated with air and varices can appear more flattened than during OCE examination. Further studies to take this into account are necessary. Nevertheless, OCE remains a useful tool for screening of varices in certain patient groups; patients who poorly tolerate endoscopy or who have significant comorbidity, thus increasing the risks of repeated endoscopy, and patients with high risk of variant Creutzfeldt-Jakob disease. Although this technique is limited by availability and high costs, OCE can be cost-effective for variceal screening of patients with coagulation abnormalities (e.g., hemophilia) with coexisting liver disease, because it does not require prophylactic clotting factor administration, unlike conventional endoscopy. Serial capsule examinations in the same patient may provide significant diagnostic information regarding progression of varices.

Small bowel capsule endoscopy (SBCE) has been used to characterize PHE (Figure 6), and is of value in the diagnosis of this condition in patients with advanced liver disease who continue to bleed despite treatment of esophageal/gastric varices or portal gastropathy (Figure 7). The role of SBCE in portal hypertension has yet to be defined, but it is likely that it will remain a valuable tool in certain groups of patients with liver disease.

**Endoscopic retrograde cholangiography**

Primary sclerosing cholangitis (PSC) is characterized by fibrosis of both intrahepatic and/or extrahepatic biliary ducts. These patients are at risk of developing infectious cholangitis and up to 20% develop cholangiocarcinoma. A strategy of initial magnetic resonance cholangiopancreatography (MRCP) followed, if necessary, by ERCP is currently the most cost-effective approach to the work-up of patients with suspected sclerosing cholangitis\(^7\). ERCP plus diagnostic brushing have a sensitivity of 60%-100%, and specificity of 85%-89% in differentiating between a benign dominant stricture and cholangiocarcinoma\(^7\). Recently, two advanced cytological techniques (digital image analysis and fluorescence in situ hybridization) have been used for the detection of malignancy in PSC-related strictures and have proved to be more sensitive and equally specific to conventional cytology\(^7\).

In addition, ERCP permits therapeutic interventions with balloon dilation or stent placement as appropriate.

**Novel techniques and the biliary tree**

Novel endoscopic modalities have been compared with conventional ERCP and brush cytology. Transpapillary cholangioscopy with tissue sampling has proved to be more sensitive (92% vs 66%) and specific (93% vs 51%) than ERCP to detect cholangiocarcinoma in PSC\(^8\). In a small study, narrow band imaging has demonstrated superior visualization of biliary lesions compared with conventional white light imaging\(^8\). In another study, transpapillary intraductal ultrasound was superior to ERCP for the detection of cholangiocarcinoma in PSC in terms of sensitivity (87.5% vs 62.5%) and specificity (90.6% vs 53.1%)\(^8\).

Spyglass\(^TM\) is a new single-operator system used for the diagnosis of a variety of pancreatobiliary disorders, such as the definition of indeterminate strictures and filling defects prior to stone extraction\(^8\). Although the
Figure 8  Endomicroscopy image. A: Image from Cellvizio® bile duct endomicroscopy. The regular reticular pattern of thin dark structures with low signal (dark) characterized the normal bile duct (Image courtesy of www.cellvizio.net); B: Abnormal bile duct appearances in Cellvizio® endomicroscopy; isolated blood vessels with very strong signal (with strands) suggestive of tumor neovascularization of cholangiocarcinoma (Image courtesy of www.cellvizio.net); C: Reticular pattern of dark bands and dark clumps or glands suggestive of cholangiocarcinoma (Image courtesy of www.cellvizio.net).

initial experience is promising, the modality has been only been tested in a limited number of PSC-related strictures, and unlike ERCP, this is a purely diagnostic technique.

Confocal laser endomicroscopy ("miniprobe") is a new field of endoluminal imaging that offers extremely high magnification and resolution. This technique allows visualization of pancreatic and biliary ducts. In a pilot study of 14 patients with biliary strictures, miniprobe-based microscopy after fluorescein administration proved to be more accurate than brushings and biopsy in distinguishing benign from malignant strictures (Figure 8)[84].

A novel alternative is direct cholangioscopy using ultra-slim endoscopes (4.9-5.9 mm). These endoscopes, initially developed for transnasal endoscopy, can be safely inserted into the bile duct following sphincterotomy, and not only permit high-resolution images, but also biopsy and other interventional procedures in the bile ducts, such as hydraulic lithotripsy and division of strictures in benign biliary disease. This technique is currently under development and after a full range of endoscopic accessories are available for endobiliary interventions, it could be an effective and safe approach for patients with difficult to manage biliary disease[85].

**Endoscopic modalities in the lower GI tract**

In comparison to the upper GI tract, colonic manifestations of portal hypertension much less often present with acute bleeding, and are more often found incidentally or during investigation of anemia. As such, data are sparse and less consistent. The reported prevalence of portal hypertensive colopathy is 24%-86.

The most significant feature of portal hypertension in the colon is arguably the presence of rectal varices. These can be present in up to 44% of patients with cirrhosis at colonoscopy, although the reported prevalence varies widely. They are more frequent in patients with advanced liver disease[87].

Although bleeding from rectal varices is uncommon, it can be life threatening. Due to their rarity, no firm guidelines have been established for the management of bleeding colonic varices, and there is a limited evidence base. The most commonly used treatment modalities are sclerotherapy and band ligation. In a small retrospective comparative study of 15 patients, endoscopic injection sclerotherapy proved to be superior to endoscopic band ligation and achieved lower recurrence rates[88]. In our unit, thrombin has been successfully used to manage rectal variceal bleeding. Patients may require TIPSS if bleeding cannot be controlled endoscopically.

**ENDOSCOPY AND THE LIVER**

**TRANSPLANT PATIENT**

**Luminal diseases in liver transplant patients**

Peptic ulcer disease is the most common cause of GI bleeding in post-orthotopic liver transplant (OLT) recipients, accounting for 27% of all bleeding[89]. Varices rarely recur post-transplant, and if present, require investigation to exclude portal vein thrombosis or disease recurrence[90].

Liver transplant patients are at increased risk of opportunistic infections, particularly candidiasis and cytomegalovirus[90]. These often present with GI symptoms and require endoscopic evaluation with biopsies or brushings to confirm the diagnosis.

The association of PSC with ulcerative colitis is well recognized and is an additional risk factor for the development of colorectal cancer in immunosuppressed transplant patients. It is currently recommended that these patients have an annual surveillance colonoscopy commencing 10 years after the onset of bowel symptoms[90]. Colectomy is safe in patients who have undergone OLT, and in some high-risk cases, such as when high-grade dysplasia has already been identified, a prophylactic colectomy may be performed at the time of transplantation[91].

**Transplant-related biliary disease**

Biliary complications (biliary strictures and leaks) following liver transplantation are a challenging and common
issue that affects 10%-30% of OLT patients. Biliary strictures are classified as anastomotic or non-anastomotic \[^{[96]}\]. The initial approach in suspected post-transplant biliary strictures is usually MRCP, restricting the use of ERCP to patients who require intervention, or where MRCP results are equivocal \[^{[97]}\]. Further imaging techniques include SpyGlass \[^{[98]}\], which has been successfully used for the investigation of post-transplant biliary strictures \[^{[99]}\], and contrast-enhanced ultrasound. This is a non-invasive technique for the detection of strictures relating to hepatic artery stenosis in liver transplant patients. It provides details on the presence, location, degree, and type of stricture \[^{[100]}\]. Treatment comprises a combination of balloon dilation and stent placement, repeated if necessary until stricture resolution.

Biliary leaks can occur in up to 22% of patients. Evidence suggests that sphincterotomy with stent placement is the best treatment option for biliary leaks following OLT \[^{[101,98]}\]. Surgical revision and biliary reconstruction with the formation of hepaticojejunostomy is indicated when endoscopic or percutaneous treatment fails \[^{[102,98]}\].

In patients who have a roux-en-Y anastomosis, the technique of double balloon ERCP has been devised with promising results. The technique uses a double balloon colonoscope to approach the ampulla, although there are some limitations regarding endoscopic accessories. With further development of this technique, the endoscopic treatment of biliary complications may become easier and will play a larger role in the management of such patients \[^{[103]}\].

### CONCLUSION

Endoscopy has undergone rapid expansion with numerous novel endoscopic modalities and techniques directly applicable to the diagnosis and management of complications of liver disease. Although conventional upper GI endoscopy is still the modality of choice for esophageal varical surveillance and treatment, further options are now available with the use of capsule endoscopy and EUS. Therapeutic options for the management of upper GI bleeding in portal hypertension have also been developed. Band ligation remains the treatment of choice for esophageal varical bleeding, whereas for gastric and ectopic varices, the use of sclerostics, particularly “glue” and thrombin are increasingly being used. APC is the preferred modality for GAVE and PHG. Biliary strictures and the risk of cholangiocarcinoma are major issues in patients with PSC. ERCP is both diagnostic and therapeutic in this setting and can differentiate benign from malignant lesions in the majority of cases. Novel endoscopic techniques such as transpapillary cholangioscopy, Spyglass Direct Visualization System, confocal laser endomicroscopy (“miniprobe”) and ultra-thin cholangioscopy are increasingly being used to assist diagnosis in selected patients. Finally, in the post-liver transplant patient, upper and lower endoscopies are used to detect gastrointestinal opportunistic infections, as well as to screen for colorectal cancer in high-risk patients. Biliary complications are common after transplantation and ERCP is the modality of choice for treating such patients.

### ACKNOWLEDGMENTS

We would like to thank the Hellenic Foundation of Gastroenterology and Nutrition for providing a research scholarship to Dr. C. Krystallis.

### REFERENCES

15. Park DH, Kim MH, Lee SK, Lee SS, Choi JS, Song MH, Seo DW, Min YI. Endoscopic sphincterotomy vs. endoscopic...
papillary balloon dilation for choledechocholathiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc 2004; 60: 180-185


34 Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol 2010; 22: 905-911


45 Binmoeller KF. Glue for gastric varices: some sticky issues. Gastrointest Endosc 2000; 52: 298-301


52 Palejwala AA, Smart HL, Hughes M. Multiple pulmonary glue emboli following gastric variceal obliteration. *Endoscopy* 2000; 32: S1-S2


60 Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. *Digestion* 2008; 77: 131-137


69 de Paulo GA, Ardengh JC, Nakao FS, Ferrari AP. Treatment of esophageal varices: a randomized controlled trial comparing endoscopic sclerotherapy and EUS-guided sclerotherapy of esophageal collateral veins. *Gastrointest Endosc* 2006; 63: 396-402; quiz 463


84 Meining A, Firimberger E, Becker V, Von Delius S, Von


S-Editor Tian L  L-Editor Kerr C  E-Editor Li JY